succinylacetone has been researched along with Sensitivity and Specificity in 7 studies
succinylacetone: inhibitor of heme biosynthesis
4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tyrosinaemia type I, or fumarylacetoacetase deficiency, causes hepatorenal damage by accumulation of fumarylacetoacetate." | 1.34 | Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia. ( Ceglarek, U; Janzen, N; Kiess, W; Pfäffle, RW; Thiery, J; Weigel, JF, 2007) |
| "Succinylacetone (SUAC) is a specific marker for TYR 1 but not detectable by routine newborn screening." | 1.33 | Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. ( Goodman, SI; Gunawardena, ND; Hahn, SH; Magera, MJ; Matern, D; Mitchell, GA; Rinaldo, P; Tortorelli, S, 2006) |
| " To increase sensitivity, analytes were extracted from liver, urine, plasma and cultured nerve cells before and after dosing with DCA, derivatized to their pentafluorobenzyl esters, and analyzed via GC-MS/MS." | 1.33 | A GC-MS/MS method for the quantitative analysis of low levels of the tyrosine metabolites maleylacetone, succinylacetone, and the tyrosine metabolism inhibitor dichloroacetate in biological fluids and tissues. ( Henderson, GN; Jia, M; Liu, H; Stacpoole, PW; Zolodz, MD, 2006) |
| "When lysine was injected 30 min before 111In-DTPA-octreotide, the inhibition was 25%." | 1.29 | Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. ( Bakker, WH; Bernard, BF; Breeman, WA; de Jong, M; Krenning, EP; Rolleman, EJ; Visser, TJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sundberg, J | 1 |
| Wibrand, F | 1 |
| Lund, AM | 1 |
| Christensen, M | 1 |
| Céspedes, N | 1 |
| Valencia, A | 1 |
| Echeverry, CA | 1 |
| Arce-Plata, MI | 1 |
| Colón, C | 1 |
| Castiñeiras, DE | 1 |
| Hurtado, PM | 1 |
| Cocho, JA | 1 |
| Herrera, S | 1 |
| Arévalo-Herrera, M | 1 |
| Magera, MJ | 1 |
| Gunawardena, ND | 1 |
| Hahn, SH | 1 |
| Tortorelli, S | 1 |
| Mitchell, GA | 1 |
| Goodman, SI | 1 |
| Rinaldo, P | 1 |
| Matern, D | 1 |
| Zolodz, MD | 1 |
| Jia, M | 1 |
| Liu, H | 1 |
| Henderson, GN | 1 |
| Stacpoole, PW | 1 |
| Weigel, JF | 1 |
| Janzen, N | 1 |
| Pfäffle, RW | 1 |
| Thiery, J | 1 |
| Kiess, W | 1 |
| Ceglarek, U | 1 |
| la Marca, G | 1 |
| Malvagia, S | 1 |
| Pasquini, E | 1 |
| Innocenti, M | 1 |
| Fernandez, MR | 1 |
| Donati, MA | 1 |
| Zammarchi, E | 1 |
| de Jong, M | 1 |
| Rolleman, EJ | 1 |
| Bernard, BF | 1 |
| Visser, TJ | 1 |
| Bakker, WH | 1 |
| Breeman, WA | 1 |
| Krenning, EP | 1 |
7 other studies available for succinylacetone and Sensitivity and Specificity
| Article | Year |
|---|---|
Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
Topics: Chromatography, Liquid; Cyclohexanones; Drug Monitoring; Heptanoates; Humans; Linear Models; Nitrobe | 2018 |
Reference values of amino acids, acylcarnitines and succinylacetone by tandem mass spectrometry for use in newborn screening in southwest Colombia.
Topics: Amino Acids; Biomarkers; Carnitine; Colombia; Cross-Sectional Studies; False Positive Reactions; Hep | 2017 |
Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
Topics: Algorithms; Chromatography, Liquid; Heptanoates; Humans; Infant, Newborn; Neonatal Screening; Reprod | 2006 |
A GC-MS/MS method for the quantitative analysis of low levels of the tyrosine metabolites maleylacetone, succinylacetone, and the tyrosine metabolism inhibitor dichloroacetate in biological fluids and tissues.
Topics: Acetone; Animals; Blotting, Western; Dichloroacetic Acid; Gas Chromatography-Mass Spectrometry; Hept | 2006 |
Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia.
Topics: Blood Chemical Analysis; Blood Specimen Collection; Female; Heptanoates; Humans; Infant; Infant, New | 2007 |
The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
Topics: Biomarkers; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Female; Heptanoates; Huma | 2008 |
Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
Topics: Acetazolamide; Animals; Arginine; Cystine; Enzyme Inhibitors; Heptanoates; Kidney; Lysine; Male; Mal | 1996 |